Advisory Board October 21, 2024

Recently, retail pharmacies like CVS and Walgreens have faced significant financial difficulties, leading them to lay off workers, reduce services, and halt previously announced expansion plans.

5 PBM strategies to watch

CVS discontinues infusion services as part of cost-cutting measures

Over the last few years, CVS has struggled with declining profit margins at its retail pharmacies, as well as rising costs of patient care through its insurance unit Aetna, which generates around a third of the company’s revenue. So far, CVS has cut its 2024 earnings forecast for three straight quarters.

Currently, the company is conducting a strategic review of options, including a potential breakup of its businesses, people familiar with the matter said. CVS has also met with...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma, Pharma / Biotech
CVS, Walgreens & Walmart's healthcare strategy faces headwinds: 10 notes from 2024
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Mark Cuban's 2025 plans
Pharma At A Crossroads: Navigating Cost Pressures And Regulatory Shifts In 2025

Share This Article